Clients often ask if a law firm can represent both brand and generic drug manufacturers. It’s a reasonable question, particularly when...

We proudly partnered with several diversity-focused organizations throughout 2023, supporting events that brought together attorneys from...

On October 31, 2023, FDA approved Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen’s Stelara...

As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s...

Last week, the Seventh Circuit heard arguments in Motorola Solutions, Inc. v. Hytera Communications Corp. concerning when, if at all,...

In Hatch-Waxman litigation, method of treatment patents present unique infringement issues. Because generic drug manufacturers typically...

In the ten years since the Supreme Court ruled in Federal Trade Commission v. Actavis that reverse payment settlements—or settlements...

On December 5, the Seventh Circuit in Motorola Solutions, Inc. v. Hytera Communications Corp. will hear high-stakes arguments concerning...

The Federal Circuit's decision on claim construction, Barrday, Inc. v. Lincoln Fabrics, Inc., 2023-1903, 2023 WL 7871688 (Fed. Cir. Nov....

Axinn is a proud supporter of this year's Charting Your Own Course (CYOC) Career Development Conference, hosted by Stakeholders. For...

The U.S. International Trade Commission (ITC) has broad power to issue exclusion orders blocking the importation of goods determined to...

Expert report deadlines are a feature of every patent case's scheduling order, but they nevertheless are the constant source of disputes....

Join Axinn partners Tiffany Rider, Jimmy Attridge, and Nick Gaglio in Brussels from November 20-22 at CompLaw's Advanced EU Competition...

Does interaction between the Federal Trade Commission and other antitrust enforcers around the world benefit merging parties, or does it...

A great thing about patent litigation is the vast array of legal doctrines, arguments, and defenses that can come up in any given case....

Since the Antitrust Division's March 2022 announcement that it would once again consider and bring criminal charges for violations of...